Catalyst Pharmaceuticals (CPRX) Tops Q3 EPS by 27c, provides guidance
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.38 -0.06%
EPS Growth %: -30.9%
Financial Fact:
Loss from operations: -3.91M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -30.9%
Financial Fact:
Loss from operations: -3.91M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q3 EPS of $0.57, $0.27 better than the analyst estimate of $0.30. Revenue for the quarter came in at $128.7 million versus the consensus estimate of $123.41 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2024 revenue of $475-485 million, versus the consensus of $473.7 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kalshi in early talks for IPO - The Information
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Pfizer reaffirms 2026 guidance after CFO transition news
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
